The federal government could prevent recurrent shortages of generic sterile injectable drugs by providing extra inventories, loans for manufacturers and incentives for hospitals, according to a policy proposal by Marta Wosinska and Richard Frank, both senior fellows in economic studies at the Brookings Institution.
Key Points
-
A Medicare scorecard could get hospitals to pay for drug quality
Legislation would be required for each aspect of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?